logo
CAR Group's (ASX:CAR) five-year earnings growth trails the strong shareholder returns

CAR Group's (ASX:CAR) five-year earnings growth trails the strong shareholder returns

Yahoo14-04-2025

While CAR Group Limited (ASX:CAR) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 14% in the last quarter. But that doesn't change the fact that the returns over the last five years have been very strong. We think most investors would be happy with the 130% return, over that period. Generally speaking the long term returns will give you a better idea of business quality than short periods can. Ultimately business performance will determine whether the stock price continues the positive long term trend.
Since the stock has added AU$487m to its market cap in the past week alone, let's see if underlying performance has been driving long-term returns.
We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
During five years of share price growth, CAR Group achieved compound earnings per share (EPS) growth of 2.9% per year. This EPS growth is lower than the 18% average annual increase in the share price. This suggests that market participants hold the company in higher regard, these days. And that's hardly shocking given the track record of growth. This favorable sentiment is reflected in its (fairly optimistic) P/E ratio of 47.47.
You can see below how EPS has changed over time (discover the exact values by clicking on the image).
We like that insiders have been buying shares in the last twelve months. Even so, future earnings will be far more important to whether current shareholders make money. This free interactive report on CAR Group's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.
It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. We note that for CAR Group the TSR over the last 5 years was 171%, which is better than the share price return mentioned above. And there's no prize for guessing that the dividend payments largely explain the divergence!
CAR Group shareholders are down 3.3% for the year (even including dividends), but the market itself is up 0.4%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. On the bright side, long term shareholders have made money, with a gain of 22% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 1 warning sign for CAR Group you should be aware of.
CAR Group is not the only stock insiders are buying. So take a peek at this free list of small cap companies at attractive valuations which insiders have been buying.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

UBS Sticks to Its Sell Rating for ASX (ASXFF)
UBS Sticks to Its Sell Rating for ASX (ASXFF)

Business Insider

time3 hours ago

  • Business Insider

UBS Sticks to Its Sell Rating for ASX (ASXFF)

UBS analyst Kieren Chidgey maintained a Sell rating on ASX (ASXFF – Research Report) today and set a price target of A$69.10. The company's shares closed last Tuesday at $45.35. Confident Investing Starts Here: Chidgey covers the Financial sector, focusing on stocks such as ASX , Insurance Australia Group Limited, and QBE Insurance Group Limited. According to TipRanks, Chidgey has an average return of -0.4% and a 52.38% success rate on recommended stocks. In addition to UBS, ASX also received a Sell from Morgan Stanley's Andrei Stadnik in a report issued yesterday. However, on the same day, Citi maintained a Hold rating on ASX (Other OTC: ASXFF).

ASX (ASXFF) Gets a Hold from Citi
ASX (ASXFF) Gets a Hold from Citi

Business Insider

time4 hours ago

  • Business Insider

ASX (ASXFF) Gets a Hold from Citi

Citi analyst Nigel Pittaway maintained a Hold rating on ASX (ASXFF – Research Report) today and set a price target of A$71.60. The company's shares closed last Tuesday at $45.35. Confident Investing Starts Here: According to TipRanks, Pittaway is a 4-star analyst with an average return of 3.6% and a 57.44% success rate. Pittaway covers the Financial sector, focusing on stocks such as Challenger , QBE Insurance Group Limited, and ASX . The word on The Street in general, suggests a Moderate Sell analyst consensus rating for ASX with a $42.99 average price target. The company has a one-year high of $50.05 and a one-year low of $36.25. Currently, ASX has an average volume of 641.

ASX Penny Stocks: EMVision Medical Devices Leads Our Trio Of Picks
ASX Penny Stocks: EMVision Medical Devices Leads Our Trio Of Picks

Yahoo

time5 hours ago

  • Yahoo

ASX Penny Stocks: EMVision Medical Devices Leads Our Trio Of Picks

As Australian shares are set to advance slightly, buoyed by positive U.S. inflation data and a stable commodities market, investors are keenly observing the opportunities within the local stock landscape. Despite its vintage feel, the term 'penny stocks' continues to hold relevance for those interested in smaller or newer companies that offer both affordability and growth potential. In this article, we explore three penny stocks that stand out for their financial strength and potential for long-term value creation. Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$1.735 A$81.85M ★★★★★★ GTN (ASX:GTN) A$0.605 A$115.47M ★★★★★★ IVE Group (ASX:IGL) A$2.76 A$425.54M ★★★★★☆ Southern Cross Electrical Engineering (ASX:SXE) A$1.67 A$441.56M ★★★★★★ Tasmea (ASX:TEA) A$3.10 A$730.43M ★★★★★☆ Regal Partners (ASX:RPL) A$2.22 A$746.28M ★★★★★★ Accent Group (ASX:AX1) A$1.805 A$1.09B ★★★★☆☆ Lindsay Australia (ASX:LAU) A$0.705 A$223.61M ★★★★☆☆ Bisalloy Steel Group (ASX:BIS) A$3.27 A$155.16M ★★★★★★ CTI Logistics (ASX:CLX) A$1.79 A$144.17M ★★★★☆☆ Click here to see the full list of 1,006 stocks from our ASX Penny Stocks screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: EMVision Medical Devices Ltd focuses on the research, development, and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring, along with other medical imaging needs in Australia, with a market cap of A$156.92 million. Operations: The company generates revenue primarily from the research and development of medical device technology, amounting to A$8.06 million. Market Cap: A$156.92M EMVision Medical Devices Ltd, with a market cap of A$156.92 million, remains pre-revenue as it focuses on developing its neurodiagnostic technology. The company has more cash than debt and maintains a stable cash runway exceeding one year. Recent developments include the commencement of a pivotal trial for its emu™ Brain Scanner, aimed at stroke diagnosis and potentially supporting FDA clearance. This trial could pave the way for future product expansions in the medical imaging field. EMVision's board recently welcomed Carmel Monaghan as an Independent Non-Executive Director, bringing extensive healthcare experience to support strategic growth initiatives. Unlock comprehensive insights into our analysis of EMVision Medical Devices stock in this financial health report. Explore historical data to track EMVision Medical Devices' performance over time in our past results report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: LGI Limited focuses on carbon abatement and renewable energy solutions using biogas from landfill, with a market cap of A$267.31 million. Operations: The company generates revenue from Carbon Abatement (A$17.03 million), Renewable Energy (A$15.05 million), and Infrastructure Construction and Management (A$2.21 million). Market Cap: A$267.31M LGI Limited, with a market cap of A$267.31 million, is generating revenue from Carbon Abatement (A$17.03 million), Renewable Energy (A$15.05 million), and Infrastructure Construction and Management (A$2.21 million). Despite the company's earnings contracting by 15.3% over the past year, its debt management remains strong with operating cash flow covering 34.4% of its debt and a reduced debt-to-equity ratio from 146.5% to 46.2% over five years. While LGI's net profit margin has decreased to 17.4%, it maintains stable weekly volatility at 4%. The board is experienced, though management tenure averages only 1.3 years. Click here to discover the nuances of LGI with our detailed analytical financial health report. Understand LGI's earnings outlook by examining our growth report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: NRW Holdings Limited, with a market cap of A$1.36 billion, offers diversified contract services to the resources and infrastructure sectors in Australia through its subsidiaries. Operations: NRW Holdings generates revenue from three main segments: Mining at A$1.56 billion, MET at A$853.22 million, and Civil at A$776.06 million. Market Cap: A$1.36B NRW Holdings, with a market cap of A$1.36 billion, demonstrates strong financial health through well-covered interest payments and operating cash flow that exceeds its debt by a large margin. The company's earnings have grown significantly by 29.9% over the past year, surpassing both its historical average and industry growth rates. Despite having low return on equity at 17.3%, NRW is trading below estimated fair value and has not diluted shareholders recently. Short-term assets exceed liabilities, indicating robust liquidity management, while recent executive changes bring seasoned leadership to the finance team with Peter Bryant as CFO starting in May 2025. Navigate through the intricacies of NRW Holdings with our comprehensive balance sheet health report here. Evaluate NRW Holdings' prospects by accessing our earnings growth report. Click this link to deep-dive into the 1,006 companies within our ASX Penny Stocks screener. Looking For Alternative Opportunities? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:EMV ASX:LGI and ASX:NWH. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store